Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1987 Feb 1;165(2):417–427. doi: 10.1084/jem.165.2.417

Simian virus 40 (SV40)-transgenic mice that develop tumors are specifically tolerant to SV40 T antigen

PMCID: PMC2188506  PMID: 3029269

Abstract

The ability to mount an immune response to simian virus 40 (SV40) T antigen was evaluated using mice from two distinct SV40 transgenic lines derived from injection of the same gene construct. Our studies demonstrate functional immune tolerance to SV40 T antigen in a SV40 transgenic line that consistently develops tumors of the choroid plexus by 7 mo of age. Antibodies to SV40 T antigen are undetectable in the serum of these animals; furthermore, mice from this line are unable to generate SV40-specific CTL after primary or secondary immunization with the virus, although they mount a normal CTL response to vaccinia virus when appropriately immunized. In contrast, we find that mice from a second transgenic line of low tumor incidence can mount a humoral response to SV40 T antigen, and upon immunization they generally respond with a vigorous cytotoxic T cell response to SV40 T antigen. These data suggest that specific immune tolerance to the product of an integrated viral oncogene may be induced, and is likely a reflection of the time in development at which the gene product first appears. Immune tolerance or responsiveness to the endogenous oncogene product may in turn play a role in the tumorigenic potential of such genes.

Full Text

The Full Text of this article is available as a PDF (651.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramczuk J., Pan S., Maul G., Knowles B. B. Tumor induction by simian virus 40 in mice is controlled by long-term persistence of the viral genome and the immune response of the host. J Virol. 1984 Feb;49(2):540–548. doi: 10.1128/jvi.49.2.540-548.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BILLINGHAM R. E., BRENT L., MEDAWAR P. B. Actively acquired tolerance of foreign cells. Nature. 1953 Oct 3;172(4379):603–606. doi: 10.1038/172603a0. [DOI] [PubMed] [Google Scholar]
  3. Banerji J., Olson L., Schaffner W. A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. Cell. 1983 Jul;33(3):729–740. doi: 10.1016/0092-8674(83)90015-6. [DOI] [PubMed] [Google Scholar]
  4. Chisari F. V., Pinkert C. A., Milich D. R., Filippi P., McLachlan A., Palmiter R. D., Brinster R. L. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science. 1985 Dec 6;230(4730):1157–1160. doi: 10.1126/science.3865369. [DOI] [PubMed] [Google Scholar]
  5. Dorsch S., Roser R. Recirculating, suppressor T cells in transplantation tolerance. J Exp Med. 1977 May 1;145(5):1144–1157. doi: 10.1084/jem.145.5.1144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gillies S. D., Folsom V., Tonegawa S. Cell type-specific enhancer element associated with a mouse MHC gene, E beta. Nature. 1984 Aug 16;310(5978):594–597. doi: 10.1038/310594a0. [DOI] [PubMed] [Google Scholar]
  7. Gillies S. D., Morrison S. L., Oi V. T., Tonegawa S. A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. Cell. 1983 Jul;33(3):717–728. doi: 10.1016/0092-8674(83)90014-4. [DOI] [PubMed] [Google Scholar]
  8. Gooding L. R. Characterization of a progressive tumor from C3H fibroblasts transformed in vitro with SV40 virus. Immunoresistance in vivo correlates with phenotypic loss of H-2Kk. J Immunol. 1982 Sep;129(3):1306–1312. [PubMed] [Google Scholar]
  9. Gooding L. R. Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J Immunol. 1977 Mar;118(3):920–927. [PubMed] [Google Scholar]
  10. Gruchalla R. S., Streilein J. W. Analysis of neonatally induced tolerance of H-2 alloantigens. II. Failure to detect alloantigen-specific T-lymphocyte precursors and suppressors. Immunogenetics. 1982;15(2):111–127. doi: 10.1007/BF00621945. [DOI] [PubMed] [Google Scholar]
  11. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 1985 May 9;315(6015):115–122. doi: 10.1038/315115a0. [DOI] [PubMed] [Google Scholar]
  12. Knowles B. B., Ford S. R., Aden D. P. Reactivity to SV40 T antigen in athymic (nude), anti-thymocyte serum-treated, and normal mice. J Immunol. 1977 Jul;119(1):79–82. [PubMed] [Google Scholar]
  13. Knowles B. B., Koncar M., Pfizenmaier K., Solter D., Aden D. P., Trinchieri G. Genetic control of the cytotoxic T cell response to SV40 tumor-associated specific antigen. J Immunol. 1979 May;122(5):1798–1806. [PubMed] [Google Scholar]
  14. Korngold R., Bennink J. R., Doherty P. C. Early dominance of irradiated host cells in the responder profiles of thymocytes from P leads to F1 radiation chimeras. J Immunol. 1981 Jul;127(1):124–129. [PubMed] [Google Scholar]
  15. Nossal G. J., Pike B. L. Functional clonal deletion in immunological tolerance to major histocompatibility complex antigens. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3844–3847. doi: 10.1073/pnas.78.6.3844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Palmiter R. D., Chen H. Y., Messing A., Brinster R. L. SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumours in transgenic mice. Nature. 1985 Aug 1;316(6027):457–460. doi: 10.1038/316457a0. [DOI] [PubMed] [Google Scholar]
  17. Pan S., Knowles B. B. Monoclonal antibody to SV40 T-antigen blocks lysis of cloned cytotoxic T-cell line specific for SV40 TASA. Virology. 1983 Feb;125(1):1–7. doi: 10.1016/0042-6822(83)90058-2. [DOI] [PubMed] [Google Scholar]
  18. Stockinger B. Cytotoxic T-cell precursors revealed in neonatally tolerant mice. Proc Natl Acad Sci U S A. 1984 Jan;81(1):220–223. doi: 10.1073/pnas.81.1.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tevethia S. S., Blasecki J. W., Waneck G., Goldstein A. L. Requirement of thymus-derived theta-positive lymphocytes for rejection of DNA virus (SV 40) tumors in mice. J Immunol. 1974 Nov;113(5):1417–1423. [PubMed] [Google Scholar]
  20. Van Dyke T., Finlay C., Levine A. J. A comparison of several lines of transgenic mice containing the SV40 early genes. Cold Spring Harb Symp Quant Biol. 1985;50:671–678. doi: 10.1101/sqb.1985.050.01.082. [DOI] [PubMed] [Google Scholar]
  21. Weigle W. O. Immunological unresponsiveness. Adv Immunol. 1973;16:61–122. doi: 10.1016/s0065-2776(08)60296-5. [DOI] [PubMed] [Google Scholar]
  22. Wood P. J., Streilein J. W. Ontogeny of acquired immunological tolerance to H-2 alloantigens. Eur J Immunol. 1982 Mar;12(3):188–194. doi: 10.1002/eji.1830120304. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES